Fig. 2: Survival outcomes between 2-cycle and 3-cycle IC of the high-risk group after PSM.

a Progression-free survival after PSM; b Overall survival after PSM; c Distant metastasis-free survival after PSM; d Locoregional recurrence-free survival after PSM.